4.7 Article

Glucose deprivation-induced endoplasmic reticulum stress response plays a pivotal role in enhancement of TRAIL cytotoxicity

Journal

JOURNAL OF CELLULAR PHYSIOLOGY
Volume 236, Issue 9, Pages 6666-6677

Publisher

WILEY
DOI: 10.1002/jcp.30329

Keywords

endoplasmic reticulum stress; glucose deprivation; TRAIL cytotoxicity

Funding

  1. National Cancer Institute [R03 CA205267, R03 CA212125, P30 CA047904, R03 CA205496, R01GM118437]
  2. Department of Defense [OC190038, W81XWH-20-1-0190]

Ask authors/readers for more resources

The combination treatment of glucose deprivation and TRAIL can induce apoptosis in tumor cells through the activation of various caspases, involving the ER stress response pathway and the mitochondria-dependent pathway.
Abnormalities of the tumor vasculature result in insufficient blood supply and development of a tumor microenvironment that is characterized by low glucose concentrations, low extracellular pH, and low oxygen tensions. We previously reported that glucose-deprived conditions induce metabolic stress and promote tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity. In this study, we examined whether the metabolic stress-associated endoplasmic reticulum (ER) stress response pathway plays a pivotal role in the enhancement of TRAIL cytotoxicity. We observed no significant cytotoxicity when human colorectal cancer SW48 cells were treated with various doses of TRAIL (2-100 ng/ml) for 4 h or glucose (0-25 mM) for 24 h. However, a combination of TRAIL and low glucose-induced dose-dependent apoptosis through activation of caspases (-8, -9, and -3). Studies with activating transcription factor 4 (ATF4), C/EBP-homologous protein (CHOP), p53 upregulated modulator of apoptosis (PUMA), or death receptor 5 (DR5)-deficient mouse embryonic fibroblasts or HCT116 cells suggest that the ATF4-CHOP-PUMA axis and the ATF4-CHOP-DR5 axis are involved in the combined treatment-induced apoptosis. Moreover, the combined treatment-induced apoptosis was completely suppressed in BH3 interacting-domain death agonist (Bid)- or Bcl-2-associated X protein (Bax)-deficient HCT116 cells, but not Bak-deficient HCT116 cells. Interestingly, the combined treatment-induced Bax oligomerization was suppressed in PUMA-deficient HCT116 cells. These results suggest that glucose deprivation enhances TRAIL-induced apoptosis by integrating the ATF4-CHOP-PUMA axis and the ATF4-CHOP-DR5 axis, consequently amplifying the Bid-Bax-associated mitochondria-dependent pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medical Laboratory Technology

Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer

Ashok K. Dilly, Brendon D. Honick, Robin Frederick, Anulekha Elapavaluru, Sachin Velankar, Hima Makala, T. Kevin Hitchens, Lesley M. Foley, Jianxia Guo, Jan H. Beumer, Lora Heather Rigatti, Yong J. Lee, David L. Bartlett, Haroon A. Choudry

Summary: In patients with appendiceal mucinous carcinoma peritonei, abundant intraperitoneal accumulation of extracellular mucus causes organ dysfunction and hampers chemotherapeutic drug delivery. Combination of bromelain and N-acetylcysteine efficiently lyses extracellular mucus, reduces tumor-related symptoms, and enhances the efficacy of chemotherapy.

TRANSLATIONAL RESEARCH (2021)

Article Engineering, Biomedical

A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death

Haozhe Huang, Yixian Huang, Yuang Chen, Zhangyi Luo, Ziqian Zhang, Runzi Sun, Zhuoya Wan, Jingjing Sun, Binfeng Lu, Lin Zhang, Jing Hu, Song Li

Summary: COX inhibition plays a crucial role in cancer therapy, and repurposing 5-ASA as a COX inhibitor in combination with DOX can improve antitumor activity. The development of FASA/DOX may represent a new and effective immunochemotherapy for various types of cancers.

BIOMATERIALS (2021)

Article Biochemistry & Molecular Biology

Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis

Rochelle Fletcher, Jingshan Tong, Denise Risnik, Brian J. Leibowitz, Yi-Jun Wang, Fernando Concha-Benavente, Jonathan M. DeLiberty, Donna B. Stolz, Reet K. Pai, Robert L. Ferris, Robert E. Schoen, Jian Yu, Lin Zhang

Summary: The study reveals that NSAIDs induce endoplasmic reticulum stress and activate BID protein to suppress tumor formation, and the immunogenic cell death effect induced by NSAIDs plays a crucial role in tumor suppression.

ONCOGENE (2021)

Article Oncology

CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade

Jingshan Tong, Xiao Tan, Xiangping Song, Man Gao, Denise Risnik, Suisui Hao, Kaylee Ermine, Peng Wang, Hua Li, Yi Huang, Jian Yu, Lin Zhang

Summary: This study found that CDK4/6 inhibitors promote immunogenic cell death of cancer cells by regulating the expression of p73 and DR5, enhancing the effects of chemotherapy and immune therapy.

CANCER RESEARCH (2022)

Review Biochemistry & Molecular Biology

The emerging role of selenium metabolic pathways in cancer: New therapeutic targets for cancer

Kalishwaralal Kalimuthu, Chenicheri K. Keerthana, Manikandan Mohan, Jaison Arivalagan, Johnson Retnaraj Samuel Selvan Christyraj, Michael A. Firer, Mohammad Haroon Asif Choudry, Ruby John Anto, Yong J. Lee

Summary: This review critically analyzes the molecular mechanisms of selenium metabolism and its potential as a therapeutic target for cancer, highlighting SECISBP2 as a novel prognostic predictor and an alternative target for cancer. Strategies to develop a novel selenium metabolism-based approach for cancer therapy are emphasized, with expectations for extensive clinical use of SECISBP2 as a specific biomarker in cancer therapy. Scientists face additional challenges, including research on anticancer peptides targeting the intracellular protein SECISBP2.

JOURNAL OF CELLULAR BIOCHEMISTRY (2022)

Article Biochemistry & Molecular Biology

BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade

Jingshan Tong, Xiao Tan, Denise Risnik, Man Gao, Xiangping Song, Kaylee Ermine, Liangfang Shen, Shaomeng Wang, Jian Yu, Lin Zhang

Summary: The study shows that inducing BET protein degradation through PROTAC approach can effectively suppress the growth of colorectal cancer by activating DR5-mediated immunogenic cell death. Additionally, DR5 is crucial for the potent antitumor effect of combining BET degradation and anti-PD-1 antibody.

ONCOGENE (2021)

Article Multidisciplinary Sciences

Interferon β drives intestinal regeneration after radiation

Brian J. Leibowitz, Guangyi Zhao, Liang Wei, Hang Ruan, Michael Epperly, Lujia Chen, Xinghua Lu, Joel S. Greenberger, Lin Zhang, Jian Yu

Summary: The cGAS-STING-dependent type I interferon response plays a critical role in driving intestinal regeneration and aiding in recovery from radiation injury. Deficiency in the STING pathway impairs epithelial IFN-beta production, inflammation, transcriptional response, and subsequent crypt regeneration, leading to impaired intestinal regeneration and survival.

SCIENCE ADVANCES (2021)

Article Biochemistry & Molecular Biology

Ferroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy

Weilin Liu, Hongqi Chen, Zhi Zhu, Zuqiang Liu, Congrong Ma, Yong J. Lee, David L. Bartlett, Zong-Sheng Guo

Summary: The study found that the combination of the ferroptosis activator Erastin with the oncolytic vaccinia virus could effectively inhibit tumor growth, prolong host survival, and enhance antitumoral immunity in hepatocellular carcinoma and colon cancer models.

BIOMEDICINES (2022)

Article Cell Biology

Involvement of Bid in the crosstalk between ferroptotic agent-induced ER stress and TRAIL-induced apoptosis

Jin Hong Kim, Abdo J. Najy, Jian Li, Xu Luo, Hyeong-Reh C. Kim, Mohammad Haroon Asif Choudry, Yong J. Lee

Summary: This study investigated the crosstalk between the ferroptotic agent-induced endoplasmic reticulum (ER) stress response and TRAIL-induced apoptosis, and found that Bid plays a critical role in this process.

JOURNAL OF CELLULAR PHYSIOLOGY (2022)

Article Oncology

Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5-and p53/PUMA-mediated cell death

Chaoyuan Kuang, Jingshan Tong, Kaylee Ermine, Manbo Cai, Fujun Dai, Suisui Hao, Francis Giles, Yi Huang, Jian Yu, Lin Zhang

Summary: The study demonstrates that NEO2734 more potently suppresses CRC cell growth than first generation BET inhibitors, inducing CRC cell apoptosis via both the intrinsic and extrinsic pathways. NEO2734 treatment simultaneously upregulates PUMA and DR5 to induce cell death, effectively suppressing CRC growth.

FRONTIERS IN ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction

Jingshan Tong, Xiao Tan, Suisui Hao, Kaylee Ermine, Xinyan Lu, Zhaojin Liu, Anupma Jha, Jian Yu, Lin Zhang

Summary: Targeting cyclin-dependent kinases (CDKs) has shown promising therapeutic potential against cancer. A recent study reveals that selective CDK4/6 inhibitors induce Death Receptor 5 (DR5) via p73, leading to increased sensitivity of colorectal cancer cells to therapy-induced apoptosis. This finding provides valuable insights into the anticancer mechanisms of CDKIs and their potential clinical applications in colorectal cancer.

ONCOGENE (2023)

Article Multidisciplinary Sciences

Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer

Suisui Hao, Jingshan Tong, Anupma Jha, Denise Risnik, Darleny Lizardo, Xinyan Lu, Ajay Goel, Patricia L. Opresko, Jian Yu, Lin Zhang

Summary: Synthetic lethality can be used to target oncogenic drivers in cancer, and in this study, it was found that WRN helicase is required for the survival of MSI CRC cells. Depletion of WRN induces p53 and PUMA, leading to apoptosis in MSI CRC cells. The vulnerability of MSI CRCs to WRN loss is mediated by p53/PUMA-dependent apoptosis. WRN depletion or treatment with ML216 suppresses the growth of MSI CRCs in vitro and in vivo in a p53/PUMA-dependent manner.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Biochemistry & Molecular Biology

Role of Receptor Interacting Protein (RIP) kinases in cancer

Kaylee Ermine, Jian Yu, Lin Zhang

Summary: The RIP kinase family plays a crucial role in cell survival and cell death signaling. Dysregulation of RIP kinases is associated with various pathological conditions including inflammatory diseases, neurological diseases, and cancer. Alterations of RIP kinases in cancer cells contribute to tumor progression, therapeutic resistance, and escape from immune response. Targeting RIP kinases has potential implications for cancer treatment.

GENES & DISEASES (2022)

Article Biochemistry & Molecular Biology

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Hang Ruan, Brian J. Leibowitz, Yingpeng Peng, Lin Shen, Lujia Chen, Charlie Kuang, Robert E. Schoen, Xinghua Lu, Lin Zhang, Jian Yu

Summary: Mutant KRAS plays a crucial role in colorectal cancer by promoting Myc translation and Myc-dependent stress adaptation and proliferation. The combination of two FDA-approved drugs, Bortezomib and Everolimus, has been found to be highly effective against mutant KRAS colorectal cancer cells. This combination rapidly depletes Myc protein and induces cell death through various pathways. The study also shows that mutant KRAS colorectal cancer cells with elevated basal Myc and p-eIF2 alpha are more sensitive to the BR combination and exhibit characteristics of stress adaptation and cell death.

MOLECULAR BIOMEDICINE (2022)

No Data Available